Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Active:	No
Cancer Type:	Multiple Myeloma	NCT ID:	NCT03651128
Trial Phases:	Phase III	Protocol IDs:	BB2121-MM-003 (primary) 2018-001023-38 NCI-2018-02057 U1111-1217-9988
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Celgene Corporation
NCI Full Details:	http://clinicaltrials.gov/show/NCT03651128

Summary

This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and
safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple
myeloma (RRMM).

The study is anticipated to randomize approximately 381 subjects with RRMM. Approximately 254
subjects will be randomized to Treatment Arm A and approximately 127 subjects will be
randomized to Treatment Arm B.

Treatment Sites in Georgia

Atlanta Cancer Care - Conyers
1498 Klondike Road
Suite 106
Conyers, GA 30094
404-303-3355
www.atlantacancercare.com

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

Study Coordinator:

Stacey Brown
404-780-7965

Doctors:

Asad Bashey MD, PhD

H. Kent Holland MD

Lawrence E. Morris, Jr. MD

Scott R. Solomon MD

Melhem Solh MD

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.